Optimizing Contrast Dose and Scanning Parameters for Detection of Leptomeningeal Disease

Recruiting now · Not applicable

Conditions studied: Leptomeningeal Disease

In brief

To learn if gadopiclenol (a contrast agent) used during MRI scanning can help in the detection of early LMD.

Key facts

Study ID

NCT07415018

Run by

M.D. Anderson Cancer Center

People needed

40

Starts

2026-06-10

Expected to finish

2029-07-31

Last updated by the study team

2026-06-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with tissue confirmed solid malignancy and standard of care brain MRI with equivocal results for LMD (questionable or possible) and negative LP CSF sampling or patients with high risk clinical LMD and negative brain MR and LP CSF sampling. Initially, we will target solid tumors, but if more patients are needed to meet the study power we will enroll liquid tumors.
• Participants > 18 years of age.
• Participants are able to consent.

You may not qualify if…

• Participants with CSF sampling positive for LMD or MR brain/spine with definitive evidence of LMD.
• Participants with implantable devices that can not be scanned with MR safe mode for participant safety.
• Pregnant participants or potentially pregnant participants are at risk of contrast on the fetus
• Pediatric participants < 18 years of age.

Where it is running

• MD Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.